Clinical trials: Second-Line
Metastatic Colorectal Cancer
The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer
This is a prospective, multi-center, randomized study evaluating the efficacy and safety of fruquintinib combined with chemotherapy vs bevacizumab combined with chemotherapy as second-line treatment in patients with metastatic…
- Trial name
- NCT05555901
- Testing
- Fruquintinib+ chemotherapy, Bevacizumab+ chemotherapy
- Where
- 13 sites in China
- Volunteers
- 116 people
- Sponsor
- Fudan University
Breast Cancer
SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases
The aim of this project is to evaluate whether the sequence of Trastuzumab，pyrotinib and Nab-Paclitaxel in first line followed by SHR-A1811 in second line is superior to the sequence of SHR-A1811 in first line followed by…
- Trial name
- NCT06975475
- Testing
- SHR-A1811,tratuzumab,pyrotinib,Nab-Paclitaxel
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Ovarian Cancer
MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer
The purpose of this study is to evaluate the activity and the toxicity of capecitabine as monotherapy in the treatment of platinum resistant or refractory ovarian cancer.
- Trial name
- NCT00403429
- Testing
- capecitabine
- Where
- 17 sites in Italy
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute, Naples
Gastric Cancer
As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers
This clinical trial is to evaluate the efficacy and safety of subjects with metastatic gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction.
- Trial name
- NCT04656002
- Testing
- Vactosertib
- Volunteers
- 43 people
- Sponsor
- Samsung Medical Center
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer
To evaluate efficacy and safety of irinotecan hydrochloride liposome in combination with 5-FU/LV as second-line treatment for locally advanced or metastatic pancreatic cancer after treatment failure with gemcitabine-based therapy.
- Trial name
- NCT05074589
- Testing
- Irinotecan liposome、5-Fluorouracil、Leucovorin
- Where
- China
- Volunteers
- 298 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chronic Heart Failure
Integration of Follow-up by First and Second Line Practitioners by Telemonitoring in Heart Failure.
The aim of this study is to evaluate this model of telemonitoring-assisted close supervision and interaction between first and second line health professionals versus a model of telemonitoring without this integrated approach.
- Trial name
- TEMA-HF2 (NCT01696890)
- Testing
- integrated follow-up, standard care
- Where
- 7 sites in Belgium
- Volunteers
- 50 people
- Sponsor
- Jessa Hospital
NSCLC (Non-small Cell Lung Cancer)
WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
This prospective Phase II study aims to evaluate the preliminary efficacy and safety of WAST cells combined with docetaxel as second-line therapy in patients with advanced NSCLC resistant to PD-1 inhibitors.
- Trial name
- NCT07330050
- Testing
- Whole Agonist-Stimulated T (WAST) cells injection, Docetaxel
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Colorectal Cancer
Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer
The primary purpose of this study is to evaluate the clinical response and safety of CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type…
- Trial name
- CRC009 (NCT01550055)
- Testing
- CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009
- Volunteers
- 512 people
- Sponsor
- Shanghai Zhangjiang Biotechnology Limited Company
Pancreatic Neoplasms
Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer
This is a single arm, single cencer, phase II clinical trial. This study aims to evaluate the efficacy and safety of Cadonilimab combined with S-1 or capecitabine as a second-line treatment for advanced pancreatic cancer.
- Trial name
- NCT06532617
- Testing
- Cadonilimab+S-1or Capecitabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Pancreatic Ductal Adenocarcinoma (mPDAC)
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with metastatic pancreatic ductal adenocarcinoma with SWItch/Sucrose…
- Trial name
- SWITCH (NCT06790602)
- Testing
- Cemiplimab Plus Gemcitabine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Diego
Obstructive Sleep Apnea Syndrome
Narval CC Mandibular Repositioning Device in the Second-line Treatment of Severe Obstructive Sleep Apnea Hypopnea (OSAH)
The purpose of this study is to evaluate the long-term efficacy, tolerance and compliance of ORM Narval Mandibular Repositioning Device (MRD) as a second-line treatment for patients with severe Obstructive Sleep Apnea Hypopnea…
- Trial name
- ORCADES (NCT01326143)
- Testing
- ORM Narval MRD
- Where
- 26 sites in France
- Volunteers
- 360 people
- Sponsor
- ResMed
Lung Cancer
ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ZD0473 in treating patients who have progressive or…
- Trial name
- NCT00021008
- Testing
- picoplatin
- Sponsor
- Jonsson Comprehensive Cancer Center
Neuroendocrine Tumor of Pancreas, Pancreatic Neuroendocrine Tumors
Patients With High-grade Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumor (pNET) is a rare form of cancer. Treatment options such as hormonal therapy (octreotide) and targeted therapy (everolimus and sunitinib) may be considered for grade 1 or 2 pNETs; however, cytotoxic…
- Trial name
- NCT07121478
- Testing
- Lurbinectedin 4 MG Injection [Zepzelca]
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- National Cancer Center, Korea
Vaginal Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma
Sac-TMT in Vaginal and Vulvar Cancers
The ARCANA trial (LACOG 1724) is a single-arm, non-randomized, multi-center, parallel, two-cohort Phase II clinical study designed to evaluate the efficacy and safety of sacituzumab tirumotecan (sac-TMT, MK-2870) as a second-line…
- Trial name
- ARCANA (NCT07804966)
- Testing
- Sacituzumab Tirumotecan (sac-TMT)
- Where
- 12 sites in Brazil
- Volunteers
- 48 people
- Sponsor
- Latin American Cooperative Oncology Group
Diabetes Mellitus, Type 2
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.
- Trial name
- BESTMED (NCT05161429)
- Testing
- DPP4, GLP-1 receptor agonist, Basal Insulin
- Where
- 5 sites in United States
- Volunteers
- 550,000 people
- Sponsor
- Brigham and Women's Hospital
Colorectal Cancer
Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab
RATIONALE: Drugs used in chemotherapy, such as irinotecan, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- BEBYP (NCT00720512)
- Testing
- bevacizumab, fluorouracil, irinotecan hydrochloride
- Where
- 21 sites in Italy
- Volunteers
- 184 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Lung Cancer
Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective in treating non-small cell lung cancer.
- Trial name
- NCT00022022
- Testing
- docetaxel, quality-of-life assessment
- Where
- 16 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Istituto Nazionale per lo Studio e la Cura dei Tumori
Helicobacter Pylori Infection
Levofloxacin Triple and Bismuth Quadruple Therapies for Rescue Treatment of H Pylori Infection
From the profiles of antibiotic susceptibility data following eradication therapy, tetracycline, amoxicillin and levofloxacin are all good candidates of antibiotics used in the rescue treatment.
- Trial name
- NCT02978157
- Testing
- esomeprazole+amox+levo, esomeprazole+bismuth+tetra+levo
- Where
- Taiwan
- Volunteers
- 102 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Non-Small Cell Lung Cancer
Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC
To evaluate the safety of the proposed Phase II dosage of the investigational drug IMO 2055 when combined with erlotinib and bevacizumab in patients with previously treated advanced NSCLC.
- Trial name
- NCT00633529
- Testing
- IMO-2055
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- EMD Serono
Stomach Cancer, Stomach Neoplasm
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
The primary objective is to evaluate six months survival rate and quality of life at 4 months of ramucirumab alone or in combination with paclitaxel in patients aged 70 years or more who have stomach or GEJ adenocarcinoma and…
- Conditions
- Stomach Cancer, Stomach Neoplasm, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- SOCRATE (NCT03760822)
- Testing
- Ramucirumab, Paclitaxel
- Where
- 38 sites in France
- Volunteers
- 112 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.